Last reviewed · How we verify
Infusion of autologous cord blood
Infusion of autologous cord blood is a Biologic drug developed by Michael Cotten. It is currently in Phase 2 development.
At a glance
| Generic name | Infusion of autologous cord blood |
|---|---|
| Sponsor | Michael Cotten |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
- Cord blood positive culture
- Seizures
- Hypertension
Key clinical trials
- Expanded Access Protocol: Umbilical Cord Blood Infusions for Children With Brain Injuries
- UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep (PHASE2)
- Hepatic Artery Transfusion of NKG2D CAR-NK Cells Followed by Intravenous Infusion of NKG2D CAR-T Cells to Treat Patients With Advanced Solid Tumors With Liver Metastases Who Have Failed Standard Treatments: a Phase I Exploratory Clinical Trial (PHASE1)
- Umbilical Cord Blood Therapy in a Child With Eosinophilic Duodenitis and Autism Spectrum Disorder: a Case Study (NA)
- A Multi-site Study of Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy (PHASE2)
- Safety and Feasibility Study of Umbilical Cord Blood Cells for Infants With Hypoplastic Left Heart Syndrome (PHASE1)
- Cord Blood for Neonatal Hypoxic-ischemic Encephalopathy (PHASE1)
- Effect of Autologous Cord Blood-mononuclear Cells Infusion on Immune Microenvironment in Infants Born Very Preterm in NICU (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Infusion of autologous cord blood CI brief — competitive landscape report
- Infusion of autologous cord blood updates RSS · CI watch RSS
- Michael Cotten portfolio CI
Frequently asked questions about Infusion of autologous cord blood
What is Infusion of autologous cord blood?
Infusion of autologous cord blood is a Biologic drug developed by Michael Cotten.
Who makes Infusion of autologous cord blood?
Infusion of autologous cord blood is developed by Michael Cotten (see full Michael Cotten pipeline at /company/michael-cotten).
What development phase is Infusion of autologous cord blood in?
Infusion of autologous cord blood is in Phase 2.
What are the side effects of Infusion of autologous cord blood?
Common side effects of Infusion of autologous cord blood include Cord blood positive culture, Seizures, Hypertension.